Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide+Decitabine+Camrelizumab vs Decitabine+Camrelizumab in Anti-PD-1 Resistant Hodgkin Lymphoma
NCT04514081Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in Hodgkin lymphoma (HL), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT04514081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04514081.